Overview

Iloprost Therapy in Patients With Critical Limb Ischemia

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
0
Participant gender:
All
Summary
Monitoring efficacy and safety aspects of iv. iloprost therapy of patients with critical limb ischemia by recording clinical parameters.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bayer
Treatments:
Iloprost
Criteria
Inclusion Criteria:

- Patients who fulfill the internationally defined criteria of critical limb ischemia;

- Patients who are not eligible for vascular surgery or angioplasty interventions and

- Patients who are treated with iloprost infusion.

- The treating physician has decided iloprost treatment before study enrollment.

Exclusion Criteria:

- Exclusion criteria are in accordance with the Summary of Product Characteristics of
Ilomedin.